CoChat

MOLECULAR BARRIERS TO XENOTRANSPLANTATION1

Lawson, Jeffrey H., Platt, Jeffrey L. · 1996 · Transplantation
Cited by 185

The DOI matches its Crossref record.

Abstract

Five years ago we explored the immunologic barriers to transplanting organs between phylogenetically disparate species (1). At that time, the primary barrier to discordant xenotransplantation seemed to be hyperacute rejection (HAR*), and we concluded this process might be initiated by one or more of four factors: (1) the binding of xenoreactive natural antibodies to their corresponding antigens expressed on endothelium of donor organs; (2) the direct activation of recipient complement via the alternative pathway on donor cells; (3) the incompatibility of donor complement regulatory proteins with the recipient complement system, which would allow for unrestrained activation of complement against the newly transplanted organ; and (4) the action of host natural killer cells on foreign endothelium. Over the past 5 years many of these ideas have been tested and basic knowledge has advanced to the point where a new thesis concerning the molecular barriers to discordant xenotransplantation can be put forward. Moreover, data have emerged which demonstrate that the barrier to xenotransplantation now extends beyond HAR. Our own studies and those of other investigators indicate that HAR of xenografts can now be averted most or perhaps all of the time. When HAR is averted, the xenograft becomes subject to one or more of the biological outcomes shown in Figure 1. In this article, we discuss these potential outcomes, emphasizing our current understanding of the cellular and molecular events that occur during the xenograft rejection process. HYPERACUTE XENOGRAFT REJECTION Susceptibility to HAR of xenotransplants has been previously considered to reflect in some quantitative way the phylogenetic distance between donor and recipient species (2-6). Yet, the characteristics of HAR suggest it is a distinct entity and not simply the extreme among a range of tissue reactions that vary continuously between species. In a given combination of donor and recipient species, HAR occurs nearly always, as in guinea pig-to-rat cardiac xenografts, or almost never, as in hamster-to-rat cardiac xenografts. There seems to be no “intermediate” state of the process. Thus, susceptibility to HAR likely reflects a discontinuous or heritable characteristic. In primate recipients, it is now clear that susceptibility to HAR of porcine organs is governed by two factors: the expression of an antigen(s) by the donor which is recognized by xenoreactive antibodies, and the relative incompatibility of donor complement regulatory proteins with the recipient's complement system (7-9). These two factors have independent genetic inheritance and the expression of each trait is not strictly related to phylogenetic distance between the donor and recipient. Xenoreactive natural antibodies and the antigens they recognize. The importance of naturally occurring xenoreactive antibodies in initiating HAR is illustrated by the following observations: (1) organs undergoing HAR contain bound immunoglobulin along vascular surfaces (10); (2) depletion of xenoreactive antibodies from the primate recipient prolongs porcine xenograft survival even when the recipient's complement system remains intact (10, 11); and (3) a porcine organ transplanted into a newborn primate that lacks xenoreactive antibodies but has an intact complement system does not undergo HAR (12). These data support the conclusion that disrupting the antibody-antigen reaction helps to mitigate HAR and provides the scientific basis for efforts to identify and modify the antigens recognized by naturally occurring xenoreactive antibodies. It is now generally accepted that the pool of xenoreactive antibodies in primates that initiate the HAR of porcine organs are specific for galactose-α(1-3)-galactose (Galα(1-3)Gal). The importance of Galα(1-3)-Gal as the primary antigen is supported by the following arguments. First, antibodies from human serum that bind to porcine cell lines can be blocked by the addition of purified α-galactosyl sugars such as Galα(1-3)Gal, but not by other saccharides (13). Second, COS cells transfected with cDNA for murine α1,3-galactosyltransferase express Galα(1-3)Gal, which allows binding of human xenoreactive antibodies and complement-mediated lysis (14). Third, removal of Galα(1-3)Gal from the surface of porcine endothelial cells prevents the binding of xenoreactive antibodies and complement deposition (15). The synthesis of Galα(1-3)Gal is catalyzed by α1,3-galactosyltransferase, which is present in all lower mammals and New World monkeys but not in humans, apes, and Old World monkeys; Old World primates and man have naturally occurring antibodies specific for that structure (16, 17). Much of the early work on xenoreactive antibodies specific for Galα(1-3)Gal focused on the IgG class of immunoglobulins (18-20). However, several lines of evidence now suggest that HAR is mediated primarily by the 2-4% of human IgM specific for the Galα(1-3)Gal epitope, rather than the IgG antibodies wit

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199608150-00001

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 185

Metadata

Authors
Lawson, J. H., & Platt, J. L.
Venue
Transplantation
Published
1996-08
Volume
62
Issue
3
Pages
303-310
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2026628669
Cited by
185
References
0
FWCI
31.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MOLECULAR BARRIERS TO XENOTRANSPLANTATION1. https://app.cochat.ai/papers/10.1097/00007890-199608150-00001
The paper
Lawson, J. H., & Platt, J. L. (1996). MOLECULAR BARRIERS TO XENOTRANSPLANTATION1. Transplantation. https://doi.org/10.1097/00007890-199608150-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.